EEF2 and depressive symptom measurement: Both pathways inhibit eEF2K activity by phosphorylation of eEF2K on e366, resulting in dephosphorization of eEF2 Thr56, suggesting that eEF2 may be a promising therapeutic target for the treatment of depression (David et al., 2020).